The store will not work correctly when cookies are disabled.
N-(cyclopropylmethyl)-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide
ID: ALA3104413
PubChem CID: 54742334
Max Phase: Preclinical
Molecular Formula: C14H15N3O3S
Molecular Weight: 305.36
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1nc(-n2ccc(O)cc2=O)sc1C(=O)NCC1CC1
Standard InChI: InChI=1S/C14H15N3O3S/c1-8-12(13(20)15-7-9-2-3-9)21-14(16-8)17-5-4-10(18)6-11(17)19/h4-6,9,18H,2-3,7H2,1H3,(H,15,20)
Standard InChI Key: KMQBABMBEFDUTM-UHFFFAOYSA-N
Molfile:
RDKit 2D
21 23 0 0 0 0 0 0 0 0999 V2000
16.2751 -18.3212 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
15.5783 -17.8874 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.5591 -17.0655 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.7705 -16.8289 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3082 -17.5083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.8084 -18.1598 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
14.4972 -16.0588 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4872 -17.5317 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.0543 -16.8360 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
13.0949 -18.2550 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
12.2333 -16.8595 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.8046 -16.1596 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.2404 -19.1421 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9330 -19.5799 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.6614 -19.1966 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.6929 -18.3749 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9960 -17.9366 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.0253 -17.1158 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
18.3564 -19.6372 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
11.7816 -15.3401 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.0817 -15.7688 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
3 4 1 0
2 3 2 0
4 5 2 0
5 6 1 0
6 2 1 0
4 7 1 0
5 8 1 0
8 9 1 0
8 10 2 0
9 11 1 0
11 12 1 0
1 13 1 0
1 17 1 0
13 14 2 0
14 15 1 0
15 16 2 0
16 17 1 0
17 18 2 0
15 19 1 0
20 12 1 0
21 20 1 0
12 21 1 0
M END
Associated Targets(Human)
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 305.36 | Molecular Weight (Monoisotopic): 305.0834 | AlogP: 1.45 | #Rotatable Bonds: 4 |
Polar Surface Area: 84.22 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 7.61 | CX Basic pKa: ┄ | CX LogP: 0.96 | CX LogD: 0.75 |
Aromatic Rings: 2 | Heavy Atoms: 21 | QED Weighted: 0.90 | Np Likeness Score: -1.40 |
References
1. Sun S, Zhang Z, Raina V, Pokrovskaia N, Hou D, Namdari R, Khakh K, Ratkay LG, McLaren DG, Mork M, Fu J, Ferreira S, Hubbard B, Winther MD, Dales N.. (2014) Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects., 24 (2): [PMID:24370012] [10.1016/j.bmcl.2013.12.035] |